UroAlert - GU Oncology Weekly

February 19, 2026

Videos

Peer-to-Peer Clinical Conversations

Nadofaragene Firadenovec Management in Real-World BCG-Unresponsive Bladder Cancer: A Case-based Discussion - Mark Tyson

Mark Tyson

Mark Tyson presents a case-based discussion on BCG-unresponsive non-muscle invasive bladder cancer treatment options.

Advancing the Management of Indeterminate Renal Masses: The Emerging Role of Molecular Imaging - Alexander Kutikov

Alexander Kutikov

Alexander Kutikov discusses indeterminate renal mass management with Zachary Klaassen.

Beyond the Abstracts

Prostate Cancer Screening in Transgender Women/Transfeminine Persons: Building on Canadian Evidence - Beyond the Abstract

Avelumab-Based Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer (AURA Oncodistinct-004): A Phase 2 Multicenter Clinical Trial - Beyond the Abstract

Conference Coverage

ASTRO Radiopharmaceutical Symposium 2026: Increasing Access to Radiopharmaceutical Therapy: From Availability to Quality Access 

SUO 2025: Development and Validation of a CHAI-based Biomarker to Prognosticate High Grade Progression risk in Low-Grade NMIBC

SUO 2025: Precystectomy ctDNA Burden is Predictive of Poor Oncological Outcomes

ESMO 2025: Post-Diagnosis Paternity in Testicular Cancer Survivors: A Controlled Cohort Study

ESMO 2025: [68Ga]Ga-DPI-4452 PET/CT for Staging of Patients with Clear Cell Renal Cell Carcinoma

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Leisure-Time Physical Activity and Cancer Mortality Among Cancer Survivors.

Oncologic outcomes after robot assisted radical cystectomy in patients with clinically positive lymph nodes (cN1): a tertiary referral center experience.

Optimal adjuvant intravesical therapy for intermediate risk non-muscle invasive bladder cancer; oncological and patient-reported outcomes of randomized controlled trial.

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

From Lichtleiter to Laser: A 200-Year Odyssey of Transurethral Resection of Bladder Tumors.

Treatment Selection for Non-Muscle-Invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.

Survival Outcomes of BCG Only, BCG Plus EMDA-MMC or Upfront Radical Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): A Multicentre, International, Collaborative Study from Tertiary Referral Institutions.

Predictors of adherence to surveillance cystoscopy for patients with non-muscle invasive bladder cancer.

Effect of extending the oral administration period of 5-aminolevulinic acid on diagnostic accuracy and treatment outcomes for non-muscle-invasive bladder cancer.

Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial.

Optimizing oncological outcomes in high-grade non-muscle invasive bladder cancer: The impact of a surgeon-led treatment pathway.

Bacillus Calmette-Guérin Plus Mitomycin versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301) - Beyond the Abstract

Differences in Bladder Cancer Diagnosis by Demographic Factors: A Simulation Modeling Analysis.

Intraoperative evaluation of detrusor muscle during transurethral resection of bladder tumour using confocal fluorescent microscopy.

Efficacy of early intravesical instillation of hyaluronic acid after transurethral resection of non-muscle-invasive bladder cancers: An open-label, prospective, single-center, randomized, controlled and parallel-group pilot study.

Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.

Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer.

A Multi-Modal Approach for Decision Making in Bladder Cancer - Beyond the Abstract

Penile & Urethral Cancers

Soluble immune checkpoint proteins as predictive biomarkers for lymph node metastases in penile cancer.

Renal Cancer

Remote Exercise Program for Patients With Metastatic Renal Cell Carcinoma Undergoing Immunotherapy: An EXIO Case Series Report.

Healthcare Research in Renal Cell Cancer: 7-Year-Data from the VERSUS Study by d-uo.

Development and Validation of Predictive Models for Trifecta Achievement in Robot-Assisted Partial Nephrectomy for Renal Hilar Tumors: Preliminary Application of the Modified R.E.N.A.L. Score.

Real-world management and clinical outcomes of first line treatment of advanced renal cell carcinoma in older patients in Canada.

Three-dimensional virtual model for robot-assisted partial nephrectomy in totally endophytic renal tumors: a propensity-score matching analysis with a control group.

Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors.

Histology-specific Prognostic Impact of Microscopic Positive Surgical Margins in Renal Cell Carcinoma: Implications for Postoperative Surveillance.

Cytoreductive nephrectomy in the era of immune-checkpoint inhibitors: back to the future?

ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma.

Systematic assessment of obesity-related risk factors in renal cancer etiology: A longitudinal risk and mendelian randomization analysis.

Response Assessment of Patients with Locally Advanced Renal Cell Carcinoma Receiving Prior Systemic Therapy - Beyond the Abstract

Prostate Cancer

Flatiron Launches First-of-Its-Kind AI-Powered Global Prostate Cancer Datasets

Characteristics and outcomes of men presenting with complications of metastatic prostate cancer.

Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial

Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions.

Diagnostic Performance of Biparametric versus Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis: An Updated Systematic Review and Meta-analysis.

Expanding Risk-adapted Early Detection of Prostate Cancer: A Call to Action for Men at High Risk.

Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases treated in a single Canadian center.

Changes over time in total Medicare costs for active surveillance versus radiotherapy in prostate cancer.

Co-PSMA: Cu-64 SAR-bisPSMA More than Doubled Prostate Cancer Lesion and Patient Detection vs. Ga-68 PSMA-11 in Head-to-Head Trial

Patient-reported outcomes: active surveillance vs radical therapies in low-risk prostate cancer.

Digital pathology-based artificial intelligence algorithms in prostate cancer: inside the 'black box'.

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy.

Reversing-or Rewiring-Lineage Plasticity? Lessons from EZH2 Loss in Prostate Cancer.

The Relationship Between Prostate Cancer Treatments and Changes to Musculature: A Systematic Review.

Contemporary methods for surgical margin assessment in radical prostatectomy: a systematic review and meta-analysis of diagnostic test accuracy.

The Italian Society of Urology Statement on focal therapy for localized prostate cancer.

Deep Learning Artificial Intelligence and Restriction Spectrum Imaging for Patient-level Detection of Clinically Significant Prostate Cancer on Biparametric Magnetic Resonance Imaging.

PSMA-guided management of recurrent post-prostatectomy patients: a sub-analysis of a prospective single-center study.

Association between baseline prostate MRI PI-RADS classification and risk of Gleason upgrade during active surveillance: a systematic review and meta-analysis.

Evaluating Potential Impacts of Climate-Related Natural Disasters on Subsequent Prostate Cancer Mortality.

FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide.

Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis.

The Impact of Race on Survival and Treatment in Veterans Treated for Metastatic Castration-Resistant Prostate Cancer.

Geographic Variability in Germline Genetic Testing for Prostate Cancer: A Nationwide Medicare Claims Study With Evidence of Low Uptake.

A Prospective Validation of the Decipher Genomic Classifier in Men With Early Localized Prostate Cancer: The VANDAAM Study.

Inter- and intra-rater variability of MRI-based lesion size measurements in active surveillance for prostate cancer: a multicentre study.

Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort.

Validation and context-dependent effects of a prostate cancer polygenic risk score in the All of Us Research Program.

Salvage radiotherapy after cryotherapy in prostate cancer.

PSMA-RADS 2.0: clinical validation and technical considerations for prostate-specific membrane antigen positron emission tomography/computed tomography image interpretation.

Automated Classification of Adverse Events after Hydrogel Perirectal Spacer Insertion for Prostate Cancer Using Large Language Models - Beyond the Abstract

Extending Current Guideline-Recommended PSA-Density Thresholds for Improving Benefit/Harm Balance in Risk-Based Magnetic Resonance Imaging-Directed Prostate Cancer Diagnosis, from the Community-Based Multicentre MR-PROPER Study - Beyond the Abstract

Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA) - Beyond the Abstract

Upper Tract Tumors

Toripalimab in Patients with Previously Treated Advanced Upper Tract Urothelial Carcinoma: A Subgroup Analysis of the Phase II POLARIS-03 Trial.

TROP2 expression is associated with early stage and favorable prognosis in upper tract urothelial carcinoma.

Initial Experience With Robot-Assisted Nephroureterectomy Using the Hugo Robot-Assisted Surgery System via a Retroperitoneal Approach: Clinical Comparison With the Transperitoneal Approach.

Testicular Cancer

Sperm banking in testicular cancer survivors: Low utilization, high costs, and patient-reported barriers from a Canadian cohort.

Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting.

Cisplatin-based chemotherapy is a possible risk factor for cerebral stroke in patients with testicular germ cell tumour - a case report and review of the literature.

Cardiovascular disease risk among long-term testicular cancer survivors following contemporary cisplatin-based chemotherapy.

Association of Y-chromosomal gr/gr deletions with testicular germ cell tumor: whole-genome analysis of 198,306 individuals.

Phthalates measured at birth and risk of testicular cancer in adolescents and young adults.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC